The World Health Organization has published a new package of essential diagnostic tests designed to help countries detect bacterial and fungal infections and identify antimicrobial resistance more reliably. Released on November 16, the 52-page toolkit is intended to help health authorities decide which laboratory tests should be available at different levels of care, from primary clinics to specialist hospitals.

Petri dish containing agar medium used for laboratory culture testing in Abuja, Nigeria
Photo: Frankincense Diala. Source · CC0.

A practical guide for diagnostic services

The Essential Package of Diagnostic Tests for Bacterial and Fungal Infections and Antimicrobial Resistance, developed under WHO’s Antimicrobial Resistance Diagnostic Initiative, brings together rapid tests, microscopy, culture-based methods, serological testing and molecular diagnostics. It maps tests to different levels of a health system and describes their purpose, specimen requirements and methods.

The aim is to make national diagnostic planning more consistent. Governments and health systems can use the package when updating essential diagnostics lists, planning procurement, deciding how services should be financed and strengthening laboratory quality systems. The WHO says access to reliable testing is central to appropriate antimicrobial use, better surveillance and improved patient outcomes.

Bacterial cell culture growing on an agar plate in a Petri dish
Photo: Syed Sajidul Islam. Source · CC BY-SA 4.0.

Why antimicrobial resistance makes diagnosis essential

Antimicrobial resistance occurs when bacteria, viruses, fungi or parasites no longer respond to medicines that are intended to treat them. The new WHO package focuses on diagnostics for bacterial and fungal infections and antimicrobial susceptibility testing, while the wider AMR challenge spans several types of pathogens and medicines.

Without appropriate testing, clinicians may have to make treatment decisions with incomplete information. Patients may receive medicines that are ineffective against the infection, while unnecessary antimicrobial use can add to the pressure that encourages resistance. Laboratory testing can help clinicians identify the organism involved and determine which medicines are more likely to work.

In a separate release published on November 16, the WHO said approximately one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotics in 2023. It also reported that 173 countries had developed national plans to address antimicrobial resistance, more than twice the 79 countries recorded in 2017. However, the agency warned that plans alone do not guarantee that patients can obtain timely testing and effective treatment.

Laboratory technician looking through a microscope during diagnostic work
Photo: Nenad Stojković. Source · CC BY 2.0.

WHO plans a global launch session on November 17

The WHO has listed a global webinar on November 17 to introduce the essential package and a related laboratory standard-operating-procedures toolkit. The session is scheduled for 13:00–14:30 Central European Time, which is 12:00–13:30 in Nigeria. The agency says the webinar will explain how the package can be applied, including how testing can be organised by level of care.

The programme lists perspectives from the WHO, the Global Leaders Group on AMR, the Global Fund, professional laboratory organisations, Nigeria’s Centre for Disease Control and other partners. The session is intended to discuss training, technical assistance, investment and collaboration. At the time of publication, the webinar was scheduled for later on Tuesday; this article does not present it as an event that has already taken place.

The challenge of turning guidance into access

The toolkit is a technical resource rather than a funding announcement or a guarantee that new tests will immediately become available in every country. Governments will still need to assess their laboratory networks, train personnel, procure equipment and reagents, maintain quality standards and ensure that test results can guide clinical decisions.

For lower-income health systems, the cost of equipment and supplies, reliable electricity, specimen transport and shortages of trained laboratory workers can all limit access. The WHO’s approach is designed to help countries prioritise tests according to the level of care and available capacity, rather than assuming that every facility can offer the same services.

HeadlinesXtra Analysis

The new package addresses one of the less visible parts of the antimicrobial-resistance crisis: the ability to identify what is causing an infection before choosing treatment. Public awareness campaigns often focus on avoiding unnecessary antibiotics, but responsible prescribing also depends on accessible laboratory services and clinicians receiving useful results in time.

The practical test will be whether ministries of health translate the WHO guidance into funded national diagnostic plans. That requires more than publishing a list. Countries need dependable procurement, laboratory staff, maintenance budgets, sample referral systems and data reporting. The toolkit gives policymakers a common reference point, but implementation will determine whether patients benefit.

Sources and Further Reading